Drugs News and Research

RSS

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.

9 Oct 2015

FDA approves expanded indication for Optune device for brain cancer patients

The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer.

9 Oct 2015

FDA announces launch of new education campaign to prevent, reduce tobacco use among hip-hop youth

The U.S. Food and Drug Administration today announced the launch of a national public education campaign to prevent and reduce tobacco use among multicultural youth who identify with the hip-hop peer crowd ‒ a group that is often hard to reach and frequently exposed to pro-tobacco images and messages. While multicultural teens identify with more than one group, the FDA is focusing on those in the hip-hop peer crowd because research estimates that they are more likely to use tobacco than other youth.

9 Oct 2015

Scientists map EGFRvIII mutant that causes brain cancer

A team of Ludwig Cancer Research scientists has mapped out how a mutant version of the epidermal growth factor receptor (EGFR) known as EGFRvIII specifically drives critical processes that alter the reading of the genome to fuel the growth of the brain cancer glioblastoma multiforme (GBM) and--most important--how each process is linked to the other.

9 Oct 2015

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition products, Contract Manufacturing, and iForce Nutrition ("iForce"), one of the fastest-growing Sports Nutrition companies in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire iForce.

9 Oct 2015

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

9 Oct 2015

Leading experts to discuss role of laboratory medicine in personalized medicine

Join the American Association for Clinical Chemistry (AACC) and leading experts in laboratory medicine and diagnostic testing for a discussion of how laboratory medicine is driving the future of personalized medicine and the policies to support these new technologies.

9 Oct 2015

Father’s life experiences can affect health, development of both children and grandchildren

If you have diabetes, or cancer or even heart problems, maybe you should blame it on your dad's behaviour or environment. Or even your grandfather's.

9 Oct 2015

Xuriden (uridine triacetate) now approved for patients with hereditary orotic aciduria

Today, the U.S. Food and Drug Administration approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria. Hereditary orotic aciduria is a rare metabolic disorder, which has been reported in approximately 20 patients worldwide.

9 Oct 2015

New partnership to deliver world-class healthcare through collaborative scientific research

A new partnership which harnesses world-class expertise will ensure patients benefit sooner from new treatments, diagnostics and prevention strategies.

9 Oct 2015

Pitt research team awarded NIH grant to study impact of substance abuse on adolescent brain development

A research team in the department of psychiatry, at the University of Pittsburgh, has been awarded a $5 Million National Institutes of Health grant to participate in a multi-site study focusing on the impact of adolescent marijuana, alcohol and other drug use on the developing brain.

9 Oct 2015

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen.

9 Oct 2015

Researchers reveal new subtypes of invasive lobular carcinoma

Researchers from the UNC Lineberger Comprehensive Cancer Center and other academic centers have revealed new subtypes of invasive lobular carcinoma, the second most commonly diagnosed invasive breast cancer type. The findings could lead to personalized treatment approaches for the disease.

9 Oct 2015

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.

9 Oct 2015

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

9 Oct 2015

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.

9 Oct 2015

Drugs News and Research

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

FDA approves expanded indication for Optune device for brain cancer patients

FDA announces launch of new education campaign to prevent, reduce tobacco use among hip-hop youth

Scientists map EGFRvIII mutant that causes brain cancer

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

Leading experts to discuss role of laboratory medicine in personalized medicine

Father’s life experiences can affect health, development of both children and grandchildren

Xuriden (uridine triacetate) now approved for patients with hereditary orotic aciduria

New partnership to deliver world-class healthcare through collaborative scientific research

Pitt research team awarded NIH grant to study impact of substance abuse on adolescent brain development

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

Researchers reveal new subtypes of invasive lobular carcinoma

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

Brain & Behavior Research Foundation to honor nine scientists with Outstanding Achievement Prizes

Scientists create first 3-D image of key protein involved in development of cancers

Repatha (evolocumab) injection gets FDA approval for high cholesterol

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News